Basal prolactin values correlate with response to reboxetine treatment in major depression, but not with response to citalopram

Neuropsychobiology

Volumn 51, Issue 2, 2005, Pages 67-71

  Moeller, Olaf ^a,b   Hetzel, Guenter ^a   Michael, Nikolaus ^a   Rothermundt, Matthias ^a   Arolt, Volker ^a   Erfurth, Andreas ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Major depression; Noradrenaline; Prolactin; Reboxetine; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DIAZEPAM; NORADRENALIN UPTAKE INHIBITOR; PROLACTIN; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; ZALEPLON;

ADRENERGIC ACTIVITY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MALE; NEUROENDOCRINOLOGY; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS;

EID: 17144378230     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084162     Document Type: Article

References (29)

1. Schmauss M, Erfurth A: Predicting antidepressive treatment success - Critical review and perspectives. Fortschr Neurol Psychiatr 1993;61:274-283.
2. Johnston TG, Kelly CB, Stevenson MR, Cooper SJ: Plasma norepinephrine and prediction of outcome in major depressive disorder. Biol Psychiatry 1999;46:1253-1258.
3. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M: Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: A prospective study. J Psychiatr Res 2001;35:83-94.
4. Arolt V, Peters M, Erfurth A, Wiesmann M, Missler U, Rudolf S, Kirchner H, Rothermundt M: S100B and response to treatment in major depression: A pilot study. Eur Neuropsychopharmacol 2003;13:235-239.
5. Gallinat J, Bottlender R, Juckel G, Munke-Puchner A, Stolz G, Kuss HJ, Mavrogjorgou P, Hegerl U: The loudness dependency of the auditory-evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology 2000;148:404-411.
6. Paige SR, Hendricks SE, Fitzpatrick DF, Balogh S, Burke WJ: Amplitude/intensity functions of auditory event-related potentials predict responsiveness to bupropion in major depressive disorder. Psychopharmacol Bull 1995;31:243-248.
7. Depue RA, Arbisi P, Krauss S, Iacono WG, Leon A, Muir R, Allen J: Seasonal independence of low prolactin concentration and high spontaneous eye blink rates in unipolar and bipolar II seasonal affective disorder. Arch Gen Psychiatry 1990;47:356-364.
8. Depue RA, Arbisi P, Spoont MR, Krauss S, Leon A, Ainsworth B: Seasonal and mood independence of low basal prolactin secretion in premenopausal women with seasonal affective disorder. Am J Psychiatry 1989;146:989-995.
9. Porter RJ, Mulder RT, Joyce PR: Baseline prolactin and L-tryptophan availability predict response to antidepressant treatment in major depression. Psychopharmacology (Berl) 2003;165:216-221.
10. Wurtman RJ, Hefti F, Melamed E: Precursor control of neurotransmitter synthesis. Pharmacol Rev 1980;32:315-335.
11. Moeller O, Hetzel G, Rothermundt M, Michael N, Nyhuis PW, Suslow T, Arolt V, Erfurth A: Oral citalopram and reboxetine challenge tests before and after selective antidepressant treatment. J Psychiatr Res 2003;37:261-262.
12. Hetzel G, Moeller O, Erfurth A, Michael N, Rothermundt M, Arolt V, Evers S: The impact of the selective monoamine reuptake inhibitors reboxetine and citalopram on visually-evoked event-related potentials in depressed patients. Pharmacopsychiatry 2004;37:200-205.
13. World Medical Association: Declaration of Helsinki. Recommendations guiding medical doctors in biomedical research involving human subjects. Med J Aust 1976;1:206-207.
14. Wittchen HO, Pfister H: Diagnostisches Expertensystem für psychische Störungen DIA-X. Frankfurt, SWETS Test Services, 1997.
15. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296.
16. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
17. 1- adrenoceptors in humans stimulates secretion of prolactin and TSH, as well as ACTH. Am J Physiol 1993;264:208-214.
18. 2 receptor agonists. Brain Res Bull 1989;23:417-424.
19. Kapoor R, Chapman IM, Willoughby JO: Alpha 2 and beta adrenoceptors in the mediobasal hypothalamus and alpha2 adrenoceptors in the preoptic-anterior hypothalamus stimulate prolactin secretion in the conscious male rat. J Neuroendocrinol 1993;5:189-193.
20. 2-adrenergic stimulation in rats. Proc Soc Exp Biol Med 1989;192:105-108.
21. Mokrani M, Duval F, Diep TS, Bailey P, Macher JP: Mulitihormonal responses to clonidine in patients with affective and psychotic symptoms. Psychoneuroendocrinology 2000;25:741-752.
22. Schule C, Baghai T, Schmidbauer S, Bidlingmaier M, Strasburger CJ, Laakmann G: Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects. Psychoneuroendocrinology 2004;29:185-200.
23. Willoughby JO, Day TA, Menadue MF, Jervois PM, Blessing WW: Adrenoceptors in the preoptic-anterior hypothalamic area stimulate secretion of prolactin but not growth hormone in the male rat. Brain Res Bull 1996;16:697-704.
24. Ueda N, Yoshimura R, Shinkai K, Nakamura J: Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression. Pharmacopsychiatry 2002;35:175-181.
25. Miller HL, Ekstrom RD, Mason GA, Lydiard RB, Golden RN: Noradrenergic function and clinical outcome in antidepressant pharmacotherapy. Neuropsychopharmacology 2001;24:617-623.
26. Coote M, Wilkins A, Werstiuk ES, Steiner M: Effects of electroconvulsive therapy and desipramine on neuroendocrine responses to the clonidine challenge test. J Psychiatry Neurosci 1998;23:172-178.
27. Correa H, Duval F, Claude MM, Bailey P, Tremeau F, Diep TS, Crocq MA, Castro JO, Macher JP: Noradrenergic dysfunction and antidepressant treatment response. Eur Neuropsychopharmacol 2001;11:163-168.
28. Shinkai K, Yoshimura R, Ueda N, Okamoto K, Nakamura J: Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharmacol 2004;24:11-17.
29. Nicholas L, Dawkins K, Golden RN: Psychoneuroendocrinology of depression. Prolactin. Psychiatr Clin North Am 1998;21:341-358.